News

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 1, 2024.

The director of Cleveland Clinic’s Mellen Center for Multiple Sclerosis Treatment and Research talked about recent findings on long-term impact of ozanimod in patients with relapsing-remitting multiple sclerosis presented at ACTRIMS Forum 2024. [WATCH TIME: 4 minutes]

A new study showed that NLRX1, a mitochondrial innate immune sensor, may serve as a promising therapeutic target to prevent inflammatory neurodegeneration in multiple sclerosis.

The chief medical advisor at the Muscular Dystrophy Association provided perspective on the upcoming meeting and the conversations surrounding new therapeutics for diseases that once had little to nothing. [WATCH TIME: 4 minutes]

A recent study presented at 2024 ACTRIMS Forum showed that body mass index may influence disease progression in patients with multiple sclerosis.

These data, presented at 2024 ACTRIMS Forum, highlight the impacts neurofilament light has on patients with multiple sclerosis irrespective of race or ethnicity.

Long-term data from the phase 3 DAYBREAK trial affirmed sustained efficacy of ozanimod for relapsing forms of multiple sclerosis, with a high amount of patients who were relapse-free at 6 years.

The program director in the division of Neuroscience at the National Institute of Neurological Disorders and Stroke provided context on the importance of Rare Disease Day and strides made over the years. [WATCH TIME: 5 minutes]

Rare Disease Day raises awareness for rare disorders, highlighting challenges, improving detection, and fostering collaboration for treatment advancements.

Caroline Just, MD, reflects on the challenges of diagnosing and treating rare neurological diseases, urging for improved education, collaboration, and research efforts.

Experts in stroke care expressed a need for significant increases in awareness of stroke risk factors and symptoms in patient communities that experience racial disparities.

Alexander Scheer, MD, medical director at Scheer Medical Wellness, provided his medical perspective on insomnia in the clinical practice of sleep medicine.

As part of our monthly clinician spotlight, NeurologyLive® highlighted sleep medicine and epilepsy expert Nancy Foldvary-Schaefer, DO, MS, director of the Sleep Disorders Center and staff in the Epilepsy Center at Cleveland Clinic.

The associate professor of neurology at McMaster University talked about findings from secondary analyses on the phase 4 ANNEXA-I trial assessing andexanet alfa in patients with acute intracerebral hemorrhage. [WATCH TIME: 10 minutes]

The director of Dysautonomia Clinic talked about the often overlooked triad of dysautonomia, hypermobility spectrum disorder, and mast cell activation syndrome in the field of headache medicine.

The conversations behind cerebroprotection in stroke have begun to get louder, with a pipeline that includes several different approaches to treatment.

A recent study showed that the 2021 European guidelines for chronic inflammatory demyelinating polyradiculoneuropathy provided a clearer definition of variants for the disease.

One of the members of the American Academy of Sleep Medicine Public Safety Committee talked about the adverse events of daylight savings among both the clinical and patient community. [WATCH TIME: 5 minutes]

ATH-1105 protected various cell culture systems from glutamate-mediated toxicity and its pathological alterations, which include mitochondrial dysfunction, apoptotic signaling, and TDP-43 mis-localization, among others.

The neurointerventional radiologist at NYU Langone provided clarity on the individualized treatment options for cervical artery dissection following a scientific statement paper from the American Heart Association. [WATCH TIME: 7 minutes]

The antisense oligonucleotide will continue to be assessed in a large-scale phase 3 study, CARDIO-TTRansform, which will have data read out in 2025.

In a recent study, a new blood test displayed remarkable accuracy in detecting Alzheimer disease pathology, showing its potential as an essential screening tool.

The director of the Comprehensive Epilepsy Center—Sleep Center at NYU Langone provided perspective on the overlap in characteristics of sleep disorders and the necessary approach to ensuring accurate diagnosis and initial treatment. [WATCH TIME: 5 minutes]

The primary result showed a highly significant effect of edaravone dexborneol on good functional outcome, defined by scores of 0 (no symptoms) or 1 (some symptoms) on the standard modified Rankin scale assessed at 90 days postrandomization.

The professor of emergency medicine at Washington University in St. Louis and associate professor of neurosurgery at UTHealth Houston talked about results from the phase 3 MOST trial assessing argatroban and eptifibatide in acute ischemic stroke. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Repetitive transcranial magnetic stimulation, a more widely used symptomatic treatment, was able to improve several outcomes for patients with cerebellar ataxia, especially at high frequencies.

The professor of neurology at University of South Florida talked about the cost-effectiveness of insertable cardiac monitors to detect new atrial fibrillation in patients with large-artery or small-vessel disease stroke. [WATCH TIME: 4 minutes]